Please login to the form below

Not currently logged in
Email:
Password:

Stage Cell Therapeutics

This page shows the latest Stage Cell Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Juno boosts CAR-T presence with $80m German acquisition

Juno boosts CAR-T presence with $80m German acquisition

Juno boosts CAR-T presence with $80m German acquisition. Stage Cell Therapeutics will contribute in process development and manufacturing. ... Juno Therapeutics has laid claim to another piece of the immuno-oncology territory by buying Germany's Stage

Latest news

  • Going for gold

    Cell Therapeutics is conducting late-stage clinical development with its solvent-free formulation ñ paclitaxel poliglumex (Xyotax). ... The paclitaxel then releases from the polymer and becomes active. Cell Therapeutics is currently conducting phase III

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    Last in its hat trick of deals this month was Juno's acquisition of Stage Cell Therapeutics for an initial payment of $59m with $150m in success payments. ... 900. Editas/Juno Therapeutics. Collaboration. Development of next generation CAR-T and TRC cell

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics